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Background
Blau Syndrome is an inherited granulomatous inflamma-
tory disorder caused by gain-of-function mutations in
NOD2, leading to activation of downstream signaling
through the RIP2 kinase and production of pro-inflam-
matory cytokines.
Aim
To identify robust biomarkers of disease activity, we
undertook a systematic analysis of whole blood gene
and plasma protein expression in Blau patients versus
normal healthy volunteers (NHVs).
Methods
Whole blood cell total RNA and plasma samples were
obtained from Blau patients (N=6) and NHVs (N=8)
a n du s e di na c c o r dw i t hi n f o r m e dc o n s e n t s .T r a n s c r i p -
tional profiling was performed using Affymetrix micro-
arrays, and immunoassays for 261 plasma proteins were
performed using multiplexed Luminex arrays. Results
were confirmed by real-time RT-PCR and ELISAs on
independent samples.
Results
By transcriptional profiling, a 21-gene signature was
identified as differentially expressed between Blau and
NHV samples. Consistent with constitutive activation of
NOD2 signaling in Blau, 14 out of 21 of these genes
were similarly regulated by NOD2 ligand stimulation in
a NHV whole blood assay (P<0.0001). Plasma protein
profiling identified a 7-protein signature specifically
upregulated in Blau relative to NHV samples. Cross
validation by PLS-DA supervised classification showed
90-100% accuracy in assigning patient disease status. Of
particular interest, the inflammatory protein S100A12
(EN-RAGE) was found to be increased by 4.6 fold in
Blau plasma (FDR P=0.005).
Conclusion
We have identified both whole blood transcriptional and
plasma protein signatures that uniquely distinguish Blau
from normal volunteers. S100A12, a recently emerging
biomarker of neutrophil-mediated inflammation, is con-
sistently upregulated in Blau patients and may be a use-
ful biomarker for monitoring disease state in future
clinical trials. Finally, bioinformatic pathway analyses
and comparisons of these findings with other known
disease signatures may provide new insights into the
pathogenesis of Blau Syndrome.
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